# Phase 2B Upper Extremity Nerve Block Study

> **NCT03011333** · PHASE2 · COMPLETED · sponsor: **Heron Therapeutics** · enrollment: 243 (actual)

## Conditions studied

- Postoperative Pain

## Interventions

- **DRUG:** HTX-011
- **DRUG:** Bupivacaine HCl without epinephrine
- **DRUG:** Saline Placebo

## Key facts

- **NCT ID:** NCT03011333
- **Lead sponsor:** Heron Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-14
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-03-19
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011333, "Phase 2B Upper Extremity Nerve Block Study". Retrieved via AI Analytics 2026-05-18 from https://api.ai-analytics.org/clinical/NCT03011333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*